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Effects of angiotensin II receptor blockade on remnant glomerular
permselectivity. This study examined the mechanisms by which angio-
tensin II (Ang II) receptor blockade improves glomerular barrier
function in rats with reduced nephron number. Proteinuria was mea-
sured at four weeks after 5/6 renal ablation, and rats were then divided
into a group which received the Ang II receptor blocker MK954 and a
group which received no treatment. Studies performed one week later
showed that Ang II receptor blockade reduced proteinuria without
altering GFR in renal ablated rats. Micropuncture studies showed that
Ang II blockade reduced both mean arterial pressure (142 7 mm Hg,
ablation without treatment; 105 2 mm Hg, ablation with treatment)
and glomerular transcapillary pressure (54 3mm Hg, ablation without
treatment; 43 1 mm Hg, ablation with treatment). Dextran sieving
studies showed that untreated rats developed a size-selective defect
characterized by increased transglomerular passage of neutral dextrans
with radii 54 to 76 A and a charge-selective defect characterized by an
increased trans1omerular passage of anionic dextran sulfate with a
radius of —18 A. Ang II blockade reduced fractional clearance values
for large neutral dextrans near to values observed in normal rats but had
no effect on the fractional clearance of dextran sulfate (0.68 0.11,
ablation without treatment; 0.66 0.08, ablation with treatment; 0.46
0.05, normal rats). These findings indicate that reducing Ang II activity
improves size-selectivity without affecting charge-selectivity in injured
remnant glomeruli.
Rats subjected to reduction in nephron number develop
glomerular injury characterized initially by proteinuria and later
by glomerular sclerosis. Treatment with angiotensin converting
enzyme inhibitors from the time of ablation has been shown to
protect against the development of glomerular injury in these
animals [ 1—3]. Two recent studies have shown that converting
enzyme inhibition and Ang II receptor blockade also reduce
proteinuria in renal ablated rats with established glomerular
injury [4, 5]. These studies suggest that the beneficial effect of
converting enzyme inhibition on the permselective function of
remnant glomeruli is due to reduction in Ang II activity. Other
studies have shown that converting enzyme inhibition reduces
proteinuria in different experimental and clinical renal diseases
[6—13]. These findings have stimulated interest in the mecha-
nisms by which reducing Ang II activity can repair defects in
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glomerular permselectivity [9, 12, 13]. The current study used
dextran sieving techniques to characterize the permselective
defects responsible for proteinuria in rats with reduced nephron
number. A non-peptide Ang II receptor blocker was adminis-
tered to determine whether reduction of Ang II activity could
repair these defects [14]. The effects of Ang II blockade on
size-selectivity were assessed by measuring the clearance of
uncharged dextrans of graded size and the effects of Ang II
blockade on charge-selectivity were assessed by measuring the
clearance of anionic dextran sulfate. Previously described the-
oretical models were used to relate changes in the clearance of
dextrans to changes in glomerular membrane pore structure [13,
15]. Clearances of uncharged dextrans with radii up to 76 A
were measured to enhance the precision with which membrane
pore size parameters could be calculated.
Methods
Remnant glomerular function was studied in male Munich
Wistar rats subjected to 5/6 renal ablation as previously de-
scribed [1]. Separate groups of rats were used for studies of
neutral dextran clearance (Group 1), anionic dextran sulfate
clearance (Group 2), and glomerular hemodynamic function
(Group 3). Each group was divided into two subgroups follow-
ing measurements of systolic blood pressure, 24-hour urine
protein excretion, and serum creatinine concentration at four
weeks after ablation. Groups 1A (N = 7), 2A (N = 8), and 3A
(N = 5) then received no treatment while Groups lB (N 8),
2B (N = 7), and 3B (N = 6) received the angiotensin II receptor
blocker, MK 954 (Merck Sharpe & Dohme, West Point, Penn-
sylvania, USA) at a dose of 360 mg/liter in their drinking water.
(MK 954 has also been designated DuP 753.) Studies of MK 954
in rats with Goldblatt hypertension provided the basis for
selecting this dose [14]. One week after rats were divided into
treated and untreated subgroups, measurements of blood pres-
sure and protein excretion were repeated and the rats then
underwent either dextran clearance or micropuncture studies.
Control measurements of neutral dextran clearance (Group 1 C,
N 16) and anionic dextran sulfate clearance (Group 2C, N =
8) were obtained in normal rats with intact kidneys.
Functional studies
Surgical procedure. Rats were anesthetized with mactin, 100
mg/kg intraperitoneally, and placed on a temperature-regulated
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micropuncture table. A PE-50 tubing catheter was inserted into
the left femoral artery and used for subsequent blood sampling
and estimation of mean arterial pressure (AP). After tracheos-
tomy, PE-50 catheters were inserted into the right and left
jugular veins for infusion of rat plasma, saline, and clearance
markers. Rat plasma was infused in an amount equal to 1%
body weight over 45 minutes, followed by a reduction in
infusion rate to 0.4 ml/hr for the remainder of the experiment.
Neutral dextran clearance studies (Groups JA, lB. and IC).
After the completion of surgery, renal ablated rats received a
bolus infusion of Macrodex, 6 mg over 45 minutes, and a
continuous infusion of Rheomacrodex at 6 mg/hr. [Rheomacro-
dex and Macrodex (Kabi Vitrum AB, Stockholm, Sweden) are
clinical preparations of polydisperse dextrans with peak molec-
ular weights of —40,000 and —70,000 Daltons, respectively.]
Normal rats with two kidneys received a bolus infusion of
Macrodex, 4.5 mg over 45 minutes, and a continuous infusion of
Rheomacrodex at 12 mg/hr. Both renal ablated and normal rats
received 3.0 ml of saline over 45 minutes in addition to a
continuous infusion of saline at the rate of 1.5 mllhr. Tritiated
methoxy-inulin was infused with the saline for the measurement
of GFR. Fifteen minutes after the end of the bolus infusions, a
one-hour clearance study was performed. Seven 200-pi femoral
artery blood samples were obtained at 10 minute intervals and
pooled for analysis of plasma dextran and inulin concentrations.
Urine collection was initiated two minutes after the first blood
sample to correct for ureteral transit time. Hematocrit and
plasma protein concentration were determined on the midpoint
arterial blood sample. Volume losses due to sample withdrawal
were replaced with rat plasma.
Dextran sulfate clearance studies (Groups 2A, 2B, and 2C).
A dextran sulfate preparation was obtained from Ueno Phar-
maceuticals (Osaka, Japan) and tritium labeled to an activity of
——0.9 mCilmg [16]. The tritiated material was subjected to size
exclusion using HPLC so as to obtain a fraction with a peak
molecular radius of 18 A. Beginning after the completion of
surgery, both renal ablated and normal rats received 0.5 ml of
saline as a bolus in addition to a continuous infusion of saline at
the rate of 3.0 mllhr. Labeled dextran sulfate and unlabeled
inulin were infused with the saline for measurement of dextran
sulfate clearance and GFR. After an equilibration period of —45
minutes, four femoral artery blood samples were obtained at 10
minute intervals, while urine was collected for a 30-minute
clearance study as described above.
Micropuncture studies (Groups 3A and 3B). Beginning during
surgery, saline was infused at a rate of 1.2 mi/hr. Approximately
one hour after completion of surgery, tritiated methoxy-inulin
was added to the saline, and micropuncture measurements were
carried out over two or three 30- to 40-minute clearance periods
as previously described [17, 18].
Analytical methods
Analysis of neutral dextrans. Dextran size separation of
plasma and urine was performed using a size exclusion HPLC
system consisting of two columns in series (Ultrahydrogel 250
and Ultrahydrogel 500, Waters Chromatography, Milford, Mas-
sachusetts, USA). The concentration of dextran in fractions
eluting from the column was measured using an on-line refrac-
tive index detector. Columns were calibrated using a set of
narrow dextran fractions with molecular weights determined by
light scattering (provided as a calibration kit by Pharmacia Fine
Chemicals, Upsala, Sweden). Plasma samples for HPLC anal-
ysis were deproteinized by adding 3.5 parts of 0.5 N NaOH and
then 3.5 parts 10% ZnSO4 per part plasma. Urine samples were
deproteinized by adding 1 part 0.5 N NaOH and 1 part 10%
ZnSO4. The deproteinized samples were filtered, vacuum dried,
and then reconstituted in the mobile phase of the HPLC system
(0.1 M phosphate buffer, pH 6.5) immediately prior to analysis.
The clearance of neutral dextrans over the size range 32 to 76
A was determined in the current studies. An interfering peak
prevented accurate measurement of the concentrations of
smaller dextrans in plasma. In three separate experiments the
recovery of dextran added to rat urine averaged 100 1%
across the size range studied while the recovery of dextran
added to rat plasma averaged 94 4% at 32 A and declined to
86 4% at 76 A. The coefficients of variation determined by
repeat assay of six plasma samples on different days were 3% at
32 A and 5% at 76 A.
Analysis of dextran sulfate. Concentrations of labeled dex-
tran sulfate in urine and plasma were determined by scintillation
counting. Preliminary in vitro experiments revealed that there is
significant binding of dextran sulfate to plasma proteins. The
extent of this binding was measured using a stirred cell and
ultrafiltration membrane with a nominal cutoff of 50,000 Daltons
(XM5O, Amicon Inc., Beverly, Massachusetts, USA). Filtra-
tion of dextran sulfate added to rat plasma through the test
membrane averaged 44 3% (N = 5) while filtration of dextran
sulfate added to Krebs buffer through the test membrane
averaged 91 2% (N = 4). The average binding of dextran
sulfate in plasma was thus estimated to be 52%, and clearance
values for dextran sulfate were corrected according to the
relation:
CDSCDS =
where CDs is the corrected clearance value and C is the
uncorrected clearance value calculated from the total concen-
tration of radiolabeled dextran suffate in plasma.
Other analyses. Systolic blood pressure was measured by the
tail cuff method. Urine protein was measured by the Coomassie
blue method. Serum creatinine in tail blood samples was
measured using a Beckman 2 Analyzer (Beckman Instruments,
Palo Alto, California, USA). The protein concentration of
arterial plasma was determined by a Lowry method [191.
Concentrations of unlabeled inulin in the urine and plasma of
Group 2 rats were measured by the anthrone method.
Calculations and statistics
Fractional dextran clearances (OD)were calculated using the
equation
CD
Cinulin
where CD is the dextran clearance and is the inulin
clearance. The size-selective properties of the glomerular filter
were further evaluated using a theoretical model which consid-
ers the glomerular wall to be permeated by cylindrical pores
having a lognormal distribution of radii [13, 15]. This model
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Table 1. Effects of Ang II receptor blockade on blood pressure and protein excretion in rats subjected to renal ablation
Neutral dextran studies Anionic dextran studies Micropuncture studies
Group lA Group lB Group 2A Group 2B Group 3A Group 3B
(untreated (treated (untreated (treated (untreated (treated
Weeks N=7) N=8) N=8) N=7) N5) N=6)
S mg/dl 4 1.14 0.07 1.11 0.03 1.03 0.03 1.10 0.04 1.06 0.03 1.09 0.06
SBP mm Hg 4 181 11 183 5 174 4 194 7 181 10 191 6
5 190 10b 123 3a,b 182 7 120 6l 199 10 125 6a.b
UproV mg/day 4 152 21 142 23 135 24 143 17
5 208 30b 90 12a,b 143 11 64 13a,b
120 10
201 26b
142 15
73 19al
Abbreviations are: Sr, serum creatinine; SBP, systolic blood pressure; UproV, protein excretion rate.
a P < 0.05 vs. corresponding untreated group at same time pointb P < 0.05 vs. same group at 4 weeks
Table 2. Summary of clearance studies with neutral dextran
Body wt AP Hct CA GFR
g mm Hg % gidi mI/mm
Group 1A (N = 7) 327 4 146 9 42 ia 4.5 0.2 0.95 0.l2a
ablation, no treatment
Group lB (N = 8) 316 4 107 3" 42 l 4.6 0.2 1.00 o.osa
ablation, Ang II blockade
Group 1C(N = 16) 314 5 110 2 47 1 4.4 0.1 2.82 0.12
normal controls
Abbreviations are: Body wt, body weight; AP, mean arterial pressure; Hct, hematocrit; CA, plasma protein concentration; GFR, whole animal
GFR in Group 1C obtained by doubling left kidney GFR.
a p < 0.05, Group 1A or lB vs. Group lCb P < 0.05, Group lB vs. Group 1A
allows the theoretical distribution of pore radii to be calculated
from values for neutral dextran fractional clearances, plasma
oncotic pressure (ir), glomerular transcapillary hydraulic pres-
sure (zP), and filtration fraction (FF). In the current study
values for and ir obtained in individual rats in Groups 1A
and lB were used together with mean values for zIP and FF
obtained in Groups 3A and 3B to analyze pore size distribution
in rats subjected to renal ablation. Values for 0 and irobtained
in individual rats in Group 1 C were used together with mean
values for zIP (40 mm Hg) and FF (0.30) obtained in normal rats
in previous studies [17, 18] to analyze pore size distribution in
intact animals. Values for ir were calculated from values for
total plasma protein concentration (C) as:
= l.629C + 0.294C2
A standard mathematical model was used to derive the glomer-
ular capillary ultrafiltration coefficient (Kr) from measured
parameters in Groups 3A and 3B [20]. When three groups were
compared, the statistical significance of pairwise comparisons
was assessed using the ANOVA and Sheffe's test. When two
groups were compared, statistical significance was assessed
using the t-test. Significance for all comparisons was defined as
P < 0.05. Calculations were made using Statview (Abacus
Concepts, Berkeley, California, USA) and results are ex-
pressed as means SE throughout.
Results
Blood pressure and protein excretion
The effects of Ang II receptor blockade on blood pressure
and protein excretion in rats subjected to renal ablation are
summarized in Table 1. As expected, hypertension was present
at four weeks after ablation with mean values for systemic
blood pressure ranging from 174 to 194 mm Hg in the six
experimental groups. Blood pressure remained stable or rose
slightly between four and five weeks in Groups lA, 2A, and 3A
which received no treatment. In contrast, blood pressure was
markedly reduced at five weeks in Groups lB, 2B, and 3B,
which received the Ang II receptor blocking agent. At four
weeks after ablation, hypertension was accompanied by pro-
teinuria, with values for protein excretion rate ranging from 120
to 152 mg/day in the six groups. In comparison, protein excre-
tion rates measured in a separate group of seven intact male
Munich Wistar rats of the same size averaged 16 2 mg/day.
Protein excretion rates tended to increase between four and five
weeks in renal ablated rats receiving no treatment. This in-
crease was statistically significant in Groups lA and 3A. In
contrast, reduction in blood pressure was accompanied by a
significant reduction in protein excretion rate in each group
subjected to Ang II receptor blockade.
Neutral dextran studies
Results of clearance studies with neutral dextran are summa-
rized in Table 2 and in Figure 1. Values for mean arterial
pressure under anesthesia, AP, paralleled values for SBP ob-
tained in unanesthetized rats. AP averaged 146 9 mm Hg in
untreated Group 1A rats and was reduced to 107 3 mm Hg by
Ang II blockade in Group lB rats; this latter value was no
different than that observed in normal Group lC rats with two
kidneys. Values for hematocrit (Hct) and glomerular filtration
rate (GFR) were lower in rats subjected to renal ablation than in
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normal Group 1C rats. Values for these parameters, however,
were not altered by Ang II receptor blockade. Figure 1 depicts
the fractional clearance profiles for neutral dextran molecules
with molecular radii from 32 to 76 A. Size-selectivity in normal
Group lC rats was characterized by a monotonic decline in ®D
from 5.3 0.3 x 10_I at 32 A to 3.0 0.6 x l0— at 76 A.
Compared to normal rats, Group 1A rats subjected to renal
ablation exhibited a defect in size-selectivity with significant
increases in eD for dextrans with radii > 54 A. The magnitude
of this defect increased with increasing molecular radius, so
that for dextrans with radii > 64 A, values for 0D in Group 1A
were more than twofold greater than values for ® in normal
rats. In contrast, the dextran clearance profile was close to
normal in Group I B rats which received the Ang II receptor
blocker. eD values for large dextrans in this group were
significantly lower than those observed in untreated Group 1 A
rats and not statistically different than those observed in normal
Group 1C rats.
Dextran sulfate clearance studies
Results of clearance studies with anionic dextran sulfate are
summarized in Table 3. Values for AP, Hct, CA, and GFR were
similar to those observed in rats undergoing neutral dextran
clearance studies. AP averaged 149 7 mm Hg in untreated
Group 2A rats and was reduced to 105 3 mm Hg by Ang II
blockade in Group 2B rats. The latter value was slightly but not
significantly lower than the mean value for AP of 116 4 mm
Hg obtained in normal Group 2C rats undergoing dextran
sulfate clearance studies. In both groups of rats subjected to
renal ablation, reduction of the GFR was accompanied by a
significant increase in the corrected fractional clearance of
dextran sulfate, ®s. Values for averaged 0.68 0.11 in
Group 2A, 0.66 0.08 in Group 2B, and 0.46 0.05 in Group
2C. The finding that the value for 0D5' was greater in Group 2A
than in Group 2C showed that rats subjected to renal ablation
develop a defect in glomerular charge-selectivity as has been
reported in previous studies [21]. The finding that values for® were nearly identical in Groups 2A and 2B showed that
Ang II receptor blockade did not repair this defect.
Theoretical analysis of pore size distribution
Various pore size distributions have been employed to model
transglomerular passage of neutral macromolecules [15]. In the
current study, the abilities of the lognormal pore size model and
the isoporous plus shunt model to predict observed neutral
dextran clearance profiles were initially compared. The as-
sumption of a lognormal pore size distribution more accurately
predicted the observed data in each group of rats undergoing
neutral dextran clearance studies. As illustrated in Figure 2 for
Group lA rats, the lognormal model proved superior because it
predicts a monotonic decline in El- with increasing dextran
radii, while the isoporous plus shunt model predicts a near
constant value for 0D above the radius assigned to the isopo-
rous portion of the glomerular membrane. Pore size distribution
in the lognormal model is described by the membrane parame-
ters u and s. Values for these parameters obtained in the current
study are given in Table 5. Qualitatively, values for u may be
considered to represent peak pore radii, and values for s to
determine the widths of pore size distribution curves [13, 15,
23]. In addition, Table 5 includes values for r* (5%) and r* (1%).
These parameters, as originally described by Remuzzi et al [13,
23], provide an index of the size of the largest pores in the
glomerular membrane. By definition, 5% of the glomerular
filtrate passes through pores with radii greater than r* (5%), and
1% of the glomerular filtrate passes through pores with radii
greater than r* (1%). Calculated values for the membrane
parameters indicated that pore size distribution was signifi-
cantly altered by renal ablation in the current study. As
compared to normal Group 1C rats, renal ablated rats exhibited
a decrease in u and an increase in s. These changes were
accompanied by increases in r* (5%) and r* (1%), indicating that
the prevalence of very large pores was increased at five weeks
1
0.1
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0.001
0.0001
Micropuncture studies
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0
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Fig. 1. Fractional clearance values for uncharged dextrans. The frac-
tional clearance of large dextrans was increased in renal ablated rats
receiving no treatment (Group 1A, — — —— — —) as compared to renal
ablated rats receiving the Ang H blocker (Group lB. A•) and to
intact control rats (Group 1C, —0————). *D < 0.05 Group lA vs.
Group lB; tP < 0.05 Group 1A vs. Group IC.
* Results of micropuncture studies are summarized in Table 4.
Studies in Group 3A rats yielded values similar to those
previously observed in rats subjected to renal ablation [1, 22].
Studies in Group 3B showed that the reduction in AP observed
with Ang II receptor blockade was accompanied by reductions
in glomerular capillary pressure (6) and in glomerular trans-
capillary hydraulic pressure (P). However, the mean value for
single nephron GFR (SNGFR) in Group 3B rats receiving the
30 40 50 60 70 80 Ang II receptor blocker remained close to the value observed in
Group 3A rats receiving no treatment. Maintenance of SNGFR
despite reduction in systemic and glomerular capillary pressure
was due to maintenance of single nephron plasma flow (QA) and
also to a significant increment in the glomerular ultrafiltration
coefficient (Kr) in rats receiving the Ang II receptor blocker.
The effectiveness of Ang II receptor blockade was confirmed by
assessing the pressor response to intravenous bolus infusion of
Ang II at the end of niicropuncture studies. The average pressor
response to 12.5 ng of Ang II was 25 8 mm Hg in Group 3A
versus 0 0 mm Hg in Group 3B, and the average pressor
response to 50 ng of Ang II was 57 11 mm Hg in Group 3A
versus 6 3 mm Hg in Group 3B.
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Table 3. Summary of clearance studies with dextran sulfate
Body wt
g
AP
mm Hg
Hct
%
CA
gidi
GFR
mi/mm ®DS 8s
Group 2A (N = 7) 312 2 149 7 40 ia 4.6 0.1 1.01 0.05a 0.33 0.02a 0.68 0.lla
ablation, no treatment
Group 2B (N = 8) 307 5 105 3b 40 l 4.6 0.2 1.10 0.14a 0.32 0.02a 0.66 o.o8
ablation, Ang II blockade
Group 2C (N = 8) 307 6 116 4 44 1 4.7 0.1 3.28 0.10 0.22 0.01 0.46 0.05
normal controls
Abbreviations are the same as Table 2 with addition of: ®, fractional clearance of dextran sulfate; fractional clearance of dextran sulfate
corrected for plasma protein binding.
a P < 0.05, Group 2A or 2B vs. Group 2C
b P < 0.05, Group 2B vs. Group 2A
Table 4. Summary of micropuncture studies
Body
AP GC Hct
wt g mm Hg
CA
gldl
GFR
mi/mm
SNGFR QA
ni/mm FF nI/mm
K1
ni
mm mm Hg
Group3A(N=5) 309±7 142±7 68±3 54±3 43±1 4.7±0.1 0.75±0.03 120±7 0.33±0.02 373±36 3.6±0.3
ablation, no
treatment
Group3B(N=6) 295±6 lOSa±2 58a±1 43a±1 42±1 5.0±0.2 0.80±0.05 105±4 O.28a±O.02 387±34 4.7a±0.2
ablation, Ang II
blockade
Abbreviations are the same as Tables 2 and 3 with addition of: P0g. glomerular capillary pressure; P, glomerular transcapillary hydraulic
pressure; SNGFR, single nephron GFR; FF, filtration fraction; QA' single nephron plasma flow; Kf, glomerular ultrafiltration coefficient.
a P < 0.05, Group 3B vs. Group 3A
Dextran radius, (A)
Fig. 2. Theoretical analysis of fractional clearance values for un-
charged dextrans. Values observed in Group IA are denoted (•).
Fractionalclearance values calculated using the lognormal model (—)
were closer to the observed values than fractional clearance values
calculated using the isoporous plus shunt model (— — — —). (Mean x2 =
86, lognormal model; mean , = 200, isoporous plus shunt model.)
a>
C)
CU
Ce
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C)
C
Ce
x
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Hg in Group 1C. To determine the extent to which error in the
assumed values for zP might alter conclusions regarding pore
size distribution, values for membrane parameters were recal-
culated assuming values for P of 49 mm Hg and 59 mm Hg in
Group 1A, 38 and 48mm Hg in Group 1B, and 35 and 45 mm Hg
in Group 1C. Use of these different values for iP altered the
values for u, r* (5%), and r* (1%) presented in Table 5 by <0.2
A and did not affect the statistical significance of differences
between the experimental groups.
Discussion
An initial aim of the current study was to characterize
in glomerular barrier function responsible for the
30 40 50 60 70 80 development of proteinuria in rats subjected to renal ablation.
In accord with previous studies, our results showed that pro-
teinuria following renal ablation is attributable to defects in both
the size- and charge-selective properties of remnant glomeruli
[211. In the current study, clearances of neutral dextrans with
radii up to 76 A were measured in an attempt to define more
precisely the nature of the defect in remnant glomerular size-
selectivity. Theoretically, the size-selective properties of the
after ablation in untreated rats. In Group lB rats, treatment
with the Ang II receptor blocker reduced r* (5%) and r* (1%) to
values only slightly and not significantly greater than those
observed in normal rats. The values for membrane parameters
presented in Table 5 were obtained by assuming values for zP
of 54mm Hg in Group 1A, 43 mm Hg in Group lB. and 40mm
glomerulus can be accounted for by assuming the glomerular
barrier is permeated by cylindrical pores of varying size [15].
Models employing several theoretical pore size distributions
have been examined in studies attempting to account for
increased glomerular permeability to large macromolecules in
proteinuric renal disease [15, 23—251. Among these, the "isopo-
rous plus shunt" model has proven computationally most
efficient in accounting for the clearance profiles of dextrans with
radii up to 60 A in clinical and experimental nephrosis [15, 26,
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Table 5. Theoretical membrane pore size distribution
uA s
r* (5%) r* (1%)
A
Group IA(N = 7) 42.7 l.1 1.23 0.Ola 71.7 1.la 82.7 l.3
ablation, no treatment
Group lB (N = 8) 42.4 0.8a 1.22 o.ola 68.7 0•4b 78.7
ablation, Ang II blockade
Group lC (N = 16) 46.2 0.7 1.18 0.01 68.2 0.5 76.6 0.7
normal controls
Abbreviations are: u, s, r* (1%), and r* (5%) are theoretical membrane parameters described in the text and more fully defined in references [15
and 23].
P < 0.05, Group 1A or lB vs. Group ICb P < 0.05, Group lB vs. Group IA
27]. This model assumes that the major portion of the glomer-
ular wall functions as an isoporous membrane, but that a small
fraction of the glomerular filtrate passes through "shunt" pores
that are unable to discriminate among macromolecules of
different size. Recent studies by Remuzzi et al [23], however,
showed that fractional clearance values decrease with increas-
ing molecular size for dextrans with radii up to 64 A in rats with
adriamycin nephrosis. This finding is inconsistent with the
assumption that large dextrans are filtered exclusively through
nondiscriminatory shunt pores. Theoretical analysis by Re-
muzzi et al [23] established that the dextran clearance profiles
observed in adriamycin nephrosis could be accounted for more
accurately by a lognormal pore size distribution than by the
isoporous plus shunt model. Theoretical analysis of dextran
clearance profiles in rats subjected to renal ablation in the
current study yielded similar results. As shown in Figure 1,
fractional clearance values decreased with increasing molecular
size for dextrans with radii up to 76 A in both normal and renal
ablated rats. The assumption of a lognormal pore size distribu-
tion provided a closer representation of these findings than the
assumption of an isoporous membrane plus a non-discriminat-
ing shunt, as illustrated in Figure 2. This is because the decline
in fractional clearance with increasing dextran radius from 60 to
76 A is better accounted for by the assumption of a subpopu-
lation of large pores of finite radius than by the assumption of a
macromolecule permeable "shunt." Other theoretical pore size
distributions which, like the lognormal distribution, include a
subpopulation of large pores of finite size could also be used to
analyze the clearance profiles observed in the present study
[15]. It should be noted that clearance values for dextrans
exceed clearance values for molecules with similar weight but
more spherical shape [281. Thus, studies performed with dex-
tran may overestimate the magnitude of the size defect in the
glomerular barrier.
The major aim of the current study was to assess the effect of
angiotensin II receptor blockade on glomerular barrier function
in rats subjected to renal ablation. Our purpose was to deter-
mine whether Ang II blockade could restore defective barrier
function toward normal, rather than to determine whether Ang
II blockade would prevent the development of defects in barrier
function following renal ablation. A period of four weeks
following renal ablation was therefore allowed for proteinuria to
become established. Institution of Ang II blockade after this
interval significantly reduced proteinuria. Results of neutral
dextran clearance studies showed that Ang II blockade reduced
proteinuria by restoring remnant glomerular size-selectivity
toward normal. Analysis of pore structure using the lognormal
model provided a quantitative index of changes in glomerular
size-selectivity. Increases in r* (5%) and r* (1%) in untreated
rats indicated that the number of large pores in the glomerular
barrier was increased at five weeks after renal ablation. Reduc-
tion of r* (5%) and r* (1%) to near normal values in treated rats
showed that Ang II blockade repaired glomerular size-selectiv-
ity at this stage in the course of remnant glomerular injury.
The results of dextran sulfate clearance studies revealed an
intriguing dissociation between the effects of Ang II blockade
on glomerular size- and charge-selectivity. The fractional clear-
ance of dextran sulfate, which was increased in renal ablated
rats, was unaffected by Ang II blockade. Thus, while it restored
remnant glomerular size-selectivity, Ang II blockade did not
repair the defect in remnant glomerular charge-selectivity.
These findings suggest that the proteinuria which persisted after
one week of Ang II blockade in renal ablated rats was due in
considerable part to defective charge-selectivity. The features
of glomerular structure responsible for normal glomerular bar-
rier function have not been conclusively identified, and we can
only speculate as to the reason Ang II blockade failed to
improve charge-selectivity in rats subjected to renal ablation.
Ultrastructural studies have suggested, however, that charge-
selectivity is attributable to the presence of negatively charged
molecules in the glomerular basement membrane [29, 30]. If this
suggestion is correct, the current results would indicate that the
density of negatively charged molecules in the membrane is
reduced following renal ablation and not restored toward nor-
mal by Ang II blockade. It should be noted that the turnover of
glomerular basement membrane constituents may proceed
slowly, and it is possible that the charge-selectivity of remnant
glomeruli would be improved if Ang II blockade were sustained
for a longer period. Alternatively, reduction in basement mem-
brane charge density could represent a consequence of glomer-
ular hypertrophy which cannot be reversed by Ang II blockade.
The current study affords an interesting comparison with
recent studies of the effect of converting enzyme inhibition on
glomerular permselectivity. Remuzzi et al [311 showed that
sustained treatment with a converting enzyme inhibitor pre-
vented the development of a size-selective defect in aging male
MWF/Ztm rats. Of note, they found that converting enzyme
inhibition reduced both the fraction of very large pores and the
peak pore radius in these animals. Converting enzyme inhibi-
tors have also been shown to reduce established proteinuria in
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some rodent models of glomerular disease and in a variety of
human renal diseases [4, 6, 8—13, 32]. Two recent studies have
used dextran clearance techniques to examine the mechanisms
by which converting enzyme inhibitors reduce proteinuria.
Morelli et al [12] showed that converting enzyme inhibition
improved glomerular size-selectivity in patients with diabetic
nephropathy, while Remuzzi et al [13] showed that converting
enzyme inhibition improved glomerular size-selectivity in pa-
tients with IgA nephropathy. Results of the latter study, ob-
tained in humans with proliferative glomerulonephritis, are
remarkably similar to those of the current study. Analysis of
pore size using the lognormal model showed that converting
enzyme inhibition caused a selective reduction in r* (1%) in
patients with IgA nephropathy similar to that we observed
during Ang II blockade in rats subjected to renal ablation.
Moreover, converting enzyme inhibition reduced fractional
clearance values for albumin and for large dextrans by approx-
imately the same extent in patients with IgA nephropathy. This
finding suggested that, like Ang II receptor blockade in the
current study, converting enzyme inhibition may have im-
proved glomerular size-selectivity without affecting glomerular
charge-selectivity.
Recent studies have suggested that converting enzyme inhib-
itors reduce proteinuria by increasing kinin activity rather than
by reducing Ang II activity in rats with passive Heymann
nephritis [33]. In the current study, a non-peptide Ang II
receptor blocker which does not alter kinin activity reduced
proteinuria in rats subjected to renal ablation [14]. Previous
studies have shown that acute administration of peptide Ang II
receptor blockers and of a converting enzyme inhibitor also
reduces proteinuria in this disease model [4, 5]. Together, these
findings indicate that reduction in Ang II activity improves
permselective function in rats with remnant glomerular injury.
It should be emphasized, however, that converting enzyme
inhibitors may improve permselective function by different
mechanisms in other disease models [6, 331.
In the current study, Ang II receptor blockade improved
glomerular barrier function and also reduced glomerular capil-
lary pressure. Similar results have been obtained in previous
studies of the effect of Ang II blockade on glomerular function
in rats subjected to renal ablation and in rats with renal vein
constriction [4, 5, 34]. These results do not, however, establish
that reduction in glomerular pressure causes the improvement
in glomerular barrier function observed when Ang II activity is
reduced. It should be noted that models which treat the
glomerular barrier as permeated by cylindrical pores do not
predict that altering iP should greatly alter fractional clearance
values for large macromolecules. Moreover, studies in diabetic
nephropathy have shown that converting enzyme inhibitors can
reduce proteinuria without markedly altering blood pressure or
GFR [11, 12], These studies have been taken to suggest that
reduction in Ang II activity might improve glomerular barrier
function without altering glomerular hemodynamic function.
Studies by Loon et al [35] have shown further that infusion of
Ang II in a dose sufficient to increase blood pressure and
ifitration fraction does not alter membrane pore structure or
increase proteinuria in nephrotic humans. Similarly, studies by
Heeg et al [9] have shown that infusion of Ang II increases
blood pressure and filtration fraction without reversing the
antiproteinuric effect of converting enzyme inhibition in ne-
phrotic humans. Together, these findings suggest either that the
effects of Ang II activity on glomerular permselectivity are not
hemodynamically mediated, or that sustained changes in hemo-
dynamic function are required to alter glomerular permselectiv-
ity in nephrotic humans. As discussed by Heeg et al [9], further
studies are required to establish whether or not changes in
glomentlar hemodynamic function cause changes in glomerular
barrier function when Ang II activity is reduced.
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